+44 (0)1509 263171
Please use this identifier to cite or link to this item:
|Title: ||Cryopreservation of dermal fibroblasts and keratinocytes in hydroxyethyl starch–based cryoprotectants|
|Authors: ||Naaldijk, Yahaira|
Johnson, Adiv A.
|Issue Date: ||2016|
|Publisher: ||© The Author(s). Published by BioMed Central|
|Citation: ||NAALDIJK, Y. ... et al, 2016. Cryopreservation of dermal fibroblasts and keratinocytes in hydroxyethyl starch–based cryoprotectants. BMC Biotechnology, 16 (85), 11pp.|
|Abstract: ||Background: Preservation of human skin fibroblasts and keratinocytes is essential for the creation of skin tissue banks. For successful cryopreservation of cells, selection of an appropriate cryoprotectant agent (CPA) is imperative. The aim of this study was to identify CPAs that minimize toxic effects and allow for the preservation of human fibroblasts and keratinocytes in suspension and in monolayers.
Results: We cryopreserved human fibroblasts and keratinocytes with different CPAs and compared them to fresh, unfrozen cells. Cells were frozen in the presence and absence of hydroxyethyl starch (HES) or dimethyl sulfoxide (DMSO), the latter of which is a commonly used CPA known to exert toxic effects on cells. Cell numbers were counted immediately post-thaw as well as three days after thawing. Cellular structures were analyzed and counted by labeling nuclei, mitochondria, and actin filaments. We found that successful cryopreservation of suspended or adherent keratinocytes can be accomplished with a 10% HES or a 5% HES, 5% DMSO solution. Cell viability of fibroblasts cryopreserved in suspension was maintained with 10% HES or 5% HES, 5% DMSO solutions. Adherent, cryopreserved fibroblasts were successfully maintained with a 5% HES, 5% DMSO solution.
Conclusion: We conclude that skin tissue cells can be effectively cryopreserved by substituting all or a portion of DMSO with HES. Given that DMSO is the most commonly used CPA and is believed to be more toxic than HES, these findings are of clinical significance for tissue-based replacement therapies. Therapies that require the use of keratinocyte and fibroblast cells, such as those aimed at treating skin wounds or skin burns, may be optimized by substituting a portion or all of DMSO with HES during cryopreservation protocols.|
|Description: ||This is an Open Access Article. It is published by BioMed Central under the Creative Commons Attribution 4.0 International Licence (CC BY). Full details of this licence are available at: http://creativecommons.org/licenses/by/4.0/|
|Sponsor: ||This work was supported by the project “Automated Tissue Engineering on Demand” from the Stiftungsprojekt of the Fraunhofer Society.|
|Publisher Link: ||http://dx.doi.org/10.1186/s12896-016-0315-4|
|Appears in Collections:||Published Articles (Mechanical, Electrical and Manufacturing Engineering)|
Files associated with this item:
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.